Twelve-Month Results of Tack-Optimized Balloon Angioplasty Using the Tack Endovascular System in Below-the-Knee Arteries (TOBA II BTK)
Authors: Geraghty Patrick J. , Adams George L. , Schmidt Andrej , Lichtenberg Michael , Wissgott Christian , Armstrong Ehrin J. , Hertting Klaus , Cardenas Joseph , Lichtenberg Michael , Wissgott Christian , Hertting Klaus , Armstrong Ehrin , Thieme Marcus , Ruzsa Zoltan , Staffa Robert , Golzar Jaafer , Brodmann Marianne , Holden Andrew , Shammas Nicolas , Ali Vaqar , Adams George , Carr Jeffrey , Bernardo Nelson , George Jon , Jain Ashit , Rundback John , Klein Andrew , Khan Muhammad , Ansel Gary , Das Sundeep , Soukas Peter , Walker Craig , Aggarwala Gaurav , Bose Rahul , Brechtel Klaus , Fisher Bryan , Kilaru Sashi , Merkley Bela , Attaran Robert , Chamberlin Jack , Davis Thomas , Delgado Gabriel , Dexter David , Kovach Richard , Rao Siddhartha , Schmidt Andrej , Silva Michael , Strickman Neil 
Published: September 2020

Purpose: To report the 12-month safety and efficacy outcomes of the investigational device exemption trial evaluating an implantable below-the-knee (BTK) dissection repair device. Materials and Methods: The prospective, multicenter, single-arm Tack-Optimized Balloon Angioplasty (TOBA) II BTK study ( ClinicalTrials.gov identifier NCT02942966) evaluated the Tack Endovascular System in the BTK arteries vs objective performance goals derived from a systematic review of BTK angioplasty literature. Patients presenting with Rutherford category 3–5 ischemia were eligible and were enrolled during the procedure if angioplasty resulted in dissection(s) of the BTK arteries. Between February 2017 and December 2018, the study enrolled 233 patients (mean age 74.4±10.0 years; 157 men). Most lesions (93.8%) were de novo; almost half (118/248, 47.6%) were total occlusions. Mean target lesion length was 80±49 mm. Moderate to severe calcium was present in 89 (35.8%) lesions. The 30-day primary safety endpoint was a composite of major adverse limb events (MALE) and all-cause perioperative death (POD). The primary efficacy endpoint was a composite of MALE at 6 months and 30-day POD. These safety and efficacy endpoints were assessed at 12 months as observational endpoints along with amputation-free survival (AFS), freedom from clinically-driven target lesion revascularization (CD-TLR), vessel patency, and changes from baseline in clinical and quality of life measures. Results: All patients had post-PTA dissection and received at least 1 Tack implant (range 1 to 16). The angiographic core laboratory noted successful resolution of 100% of the 341 treated dissections. At 12 months, 93.4% (170/182) of patients remained free of the composite endpoint of MALE + POD. Tacked segment patency was 81.3% and limb salvage was 96.8% at 12 months; freedom from CD-TLR and AFS were 83.1% and 89.3%, respectively. Sustained Rutherford category improvement was reported in 82.4% of evaluated patients, with 62.4% improving ≥3 categories (p<0.001). Ninety of 124 index wounds (72.5%) healed or improved. Conclusion: The Tack Endovascular System is safe and effective in the treatment of post-angioplasty BTK dissections. Twelve-month outcome data from the TOBA II BTK study demonstrate high rates of patency, limb salvage, and wound healing.